Fig. 4From: De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysisNomogram based on the competing risk analysis to predict CSD probabilities at 1-, 3-, and 5-year in stage I–II GNEC patientsBack to article page